03 Profile
Hansard to 12 November 2026 · 31,484 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Cancer
Michal Sladkowski
Vice chair elect of the British Oncology Pharmacy Association (BOPA)
Quoted in the press, across 1 topic since 4 Jun 2026
02 Quoted on · 1 of 29 topics
Michal Sladkowski: key facts
- Kind of voice
- Sector leader
- Role
- Vice chair elect of the British Oncology Pharmacy Association (BOPA)
- Quoted on
- Cancer
- Press coverage
- Quoted in the press
- Most recently quoted
- 4 Jun 2026
04 On the record · press
What Michal Sladkowski has said
- pharmaceutical-journal.com
Where Michal Sladkowski has been quoted
- Treatment for chemotherapy-resistant ovarian cancer approved for NHS usepharmaceutical-journal.com · 4 Jun 2026
How we found the articles that name Michal Sladkowski: we searched news for these terms.
- cancer
- cancer treatment
- cancer screening
- cancer waiting times
- oncology
- chemotherapy
- radiotherapy
- cancer diagnosis
Also searched with “cancer” in each of 8 national papers, and in the Guardian by editor tag, and in trade press by category. Every term for Cancer
Verbatim
“The survival benefits seen in the MIRASOL study are clinically meaningful. Many patients with platinum-resistant disease have already undergone prior lines of treatment and can experience significant treatment-related burden. A therapy that can both extend survival and reduce the disruption that treatment has on everyday life is particularly valuable.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.